Antares Pharma (ATRS) Misses Q1 EPS by 2c

Antares Pharma (NASDAQ: ATRS) reported Q1 EPS of ($0.05), $0.02 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $11.1 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• Arm Holdings beats Q1 estimates, shares fall in after-hours
• FMC Corp. (FMC) Tops Q2 EPS by 4c; lowers guidance
• Hexcel Corp. (HXL) Tops Q2 EPS by 8c ; Offers Guidance